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Background: The Taiwan CDC provided free oseltamivir to all patients with influenza infections confirmed by rapid
testing or who had clinical warning symptoms during the 2009 H1N1 influenza pandemic in Taiwan. However,
oseltamivir utilization patterns, cost, and outcomes among oseltamivir-treated patients remained unclear.
Method: A population-level, observational cohort study was conducted using the Taiwan National Health Insurance
Database from January to December 2009 to describe the use of oseltamivir.
Result: Prescription trend over weeks increased after a change in government policy and responded to the
influenza virus activity. The overall prescription rate was 22.33 per 1000 persons, with the highest prescription rate
of 116.5 for those aged 7–12 years, followed by 69.0 for those aged 13–18 years, while the lowest rate was 1.7 for
those aged ≥ 65 years. As influenza virus activity increased, the number of prescriptions for those aged ≤18 years
rose significantly, whereas no substantial change was observed for those aged ≥65 years. There were also regional
variations in terms of oseltamivir utilization and influenza complication rates.
Conclusions: Oseltamivir was widely used in the 2009 H1N1 influenza pandemic in Taiwan, particularly in those
aged 7–18 years. The number of prescriptions for oseltamivir increased with a change in government policy and
with increasing cases of pandemic influenza. Further study is needed to examine whether there is an over- or
under-use of anti-influenza drugs in different age groups or regions and to examine the current policy of public use
of anti-influenza drugs to reduce influenza-associated morbidity and mortality.
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The 2009 influenza A H1N1 pandemic was responsible
for at least 18,000 deaths worldwide from March 2009
throughout August 2010 [1]. Oseltamivir, a neuraminidase
inhibitor, is a widely-used anti-influenza agent to treat and
prevent seasonal or pandemic influenza infections. The
World Health Organization (WHO), the US Centers of
Disease and Control (CDC), and the European Centre for
Disease Prevention and Control recommend that govern-
ments stockpile and properly deliver anti-influenza agents
to diminish the impact of pandemic influenza [2-4].* Correspondence: chiahsuin123@yahoo.com.tw; mslai@ntu.edu.tw
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reproduction in any medium, provided the orDespite the reports that oseltamivir may reduce influenza
complications and hospitalizations, recent Cochrane re-
views have found that oseltamivir can mitigate influenza-
like illness (ILI) symptoms for 21 hours. However, the
authors are unable to conclude the effect of oseltamivir on
complications or transmission [5]. Based on the current
evidence, criticisms have been raised of the public policy
calling for mass oseltamivir prescription during the 2009
influenza A H1N1 pandemic [6].
In Taiwan, the first incidence of H1N1 infection was
reported on May 20, 2009 and the first death occurred
on July 30, 2009. To control viral transmission and re-
duce influenza-related morbidity and mortality, the
Taiwan Centers of Disease Control (Taiwan CDC) has
provided free antiviral agents (oseltamivir and zanamivir)
since August 15, 2009 through the Bureau of National
Health Insurance (BNHI) to all patients with influenza
infections that were confirmed by rapid diagnosticThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by WHO (including symptoms and signs suggesting oxy-
gen impairment, cardiopulmonary insufficiency or cen-
tral nervous system complications such as shortness of
breath, tachypnea, altered mental status etc.) during the
pandemic [3]. Receiving prescriptions for prophylaxis or
stockpiling purposes was not allowed in the national
health insurance program. However, under this policy,
the utilization patterns, cost, and outcomes among
oseltamivir-treated patients remained unclear. A clear
understanding of oseltamivir utilization is important in
terms of national medical resource allocation and policy
making for disease control. Meanwhile, examining the
utilization patterns of anti-influenza use can reveal
whether clinicians have followed guidelines to protect
high risk patient groups [7]. Therefore, we conducted a
population-level, observational cohort study using the
BNHI database from January to December 2009 to de-
scribe the frequency of oseltamivir use and outcomes of
influenza patients in Taiwan.
Methods
Ethics
Taiwan Centers for Disease Control Research approved
the protocol of this study and waived the need for written
informed consent because this is a retrospective study
based on data from administrative databases and involved
only minimal risk.
Data source
In 1995, a compulsory, single-payer national health in-
surance (NHI) program was implemented in Taiwan.
The NHI claims database includes complete records of
outpatient visits, hospital admissions, prescriptions, dis-
ease states and vital status for 99% of the 23 million
Taiwanese inhabitants. Influenza surveillance systems in
Taiwan have been described in another paper [8]. We
established longitudinal medical histories for each bene-
ficiary by linking several computerized administrative
and claims datasets, and National Death Registry data
through the civil identification number unique to each
beneficiary and the date of birth.
Study population
We identified patients who received oseltamivir pre-
scriptions (anatomical therapeutic chemical [ATC] clas-
sification system code J05AH02) between January 1 and
December 31, 2009. Data were further stratified ac-
cording to prescribers’ characteristics (outpatient or in-
patient use, region, and medical facility).We collected
information of prescribed drug supply days, date of pre-
scription, and total number of pills dispensed from the
pharmacy prescription database. Data on patient charac-
teristics, including age, gender, influenza diagnosis andrelated complications were obtained from inpatient and
outpatient medical records.
Statistical analysis
The primary variables included the number of oseltamivir
prescriptions and the rate of prescription per 1,000 per-
sons in the overall population and for each age group, cal-
culated with the use of 2009 census statistics in Taiwan.
Prescription trend over weeks was reported in relation to
influenza virus activity, as measured by positive H1N1
virus isolation rate from the Taiwan Centers for Disease
Control Influenza Surveillance Virology Laboratory [8].
We also estimated the expenditures for oseltamivir and
the proportion relative to the total outpatient expenditures
related to influenza treatment.
To investigate the outcomes of oseltamivir-treated pa-
tients, we reported the hospitalization rate of patients who
received oseltamivir treatment during outpatient visits and
the proportion of patients hospitalized for influenza and
related complications leading to a poor outcomes, which
was defined as respiratory failure or death. We also calcu-
lated the influenza complication rates in different age
groups and regions based on the influenza surveillance
data from Taiwan CDC.
Results
Utilization pattern
A total of 516,772 oseltamivir outpatient prescriptions
were identified in 2009 in Taiwan. In contrast to only
489 prescriptions during January and July, the number
of oseltamivir prescriptions increased dramatically after
the oseltamivir reimbursement policy began in August,
reaching its peak at week 48 and then gradually decreas-
ing after the mass vaccination program began in
November. The prescription trend was in general agree-
ment with the H1N1 influenza virus positive isolation
rate (Figure 1). Among the positive specimens in 2009
pandemic, there were 79.7% of influenza A (H1N1).
Most oseltamivir use was for those aged 7–12 years
(38.0%), whereas only 0.8% were prescribed for those
aged ≥65 years (Table 1). The overall prescription rate
was 22.33 per 1000 persons. Oseltamivir prescription
trends varied for different age groups (Figure 2). Among
all age groups, the highest prescription rate per 1000
persons was 116.5 for those aged 7–12 years, followed
by 69.0 for those aged 13–18 years, while the lowest rate
was 1.7 for those aged ≥ 65 years. The number of pre-
scriptions for those aged ≤18 years rose significantly as
influenza virus activity increased, whereas no substan-
tial change was observed for those aged ≥65 years
(Figure 2).
There was a substantial difference in oseltamivir pre-
scription rates among different regions, with higher
utilization in northern Taiwan than in southern Taiwan
Figure 1 Weekly oseltamivir outpatient prescriptions across different age groups from August to December 2009 in Taiwan and
percentage of positive influenza surveillance.
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primary care doctors, followed by 20.5% by regional hospi-
tals, and 10.9% for local hospitals and medical centers
(Figure 3). Of note, oseltamivir was mostly prescribed byTable 1 Total number and rate of oseltamivir prescription













0-6 74,432 (14.4) 51.4 139.4
7-12 196,086 (38.0) 116.5 74.5
13-18 133,153 (25.8) 69.0 65.2
19-64 108,473 (21.0) 7.0 28.8
≥65 4,139 (0.8) 1.7 54.1
Region
A 187,655 (36.4) 25.2 64.2
B 111,249 (21.6) 32.1 47.9
C 98,109 (19.0) 21.9 27.5
D 53,929 (10.4) 15.8 28.7
E 53,640 (10.4) 14.3 34.7
F 11,646 (2.3) 20·3 172.6
Note: Region A and B were in northern Taiwan. Region C was in central
Taiwan. Region D and E were in southern Taiwan. Region F was in eastern
Taiwan. Influenza with complications: influenza danger signs defined by WHO
(including symptoms and signs suggesting oxygen impairment,
cardiopulmonary insufficiency or central nervous system complications such as
shortness of breath, tachypnea, altered mental status etc.).physicians in regional hospitals and medical centers in
August, whereas prescriptions by primary care doctors
substantially increased after September (Figure 3).
A total of 487,278 patients received oseltamivir
treatment during outpatient visits and 1,535 patients
received oseltamivir therapy while hospitalized from
August and December 2009. As compared to patients
receiving outpatient treatment, a greater proportion of
hospitalized patients received oseltamivir treatment in
the age groups 0–6 and ≥65 years (Table 2).
In 2009, expenditures for oseltamivir were 14.2 mil-
lions US dollar (60.9 US dollar per 1,000 persons), ac-
counting for 37.2% of the total expenditures related to
outpatient visits for oseltamivir users.Outcomes of pandemic influenza A H1N1 and related
complications
Among the oseltamivir-treated patients, 11.2% were
diagnosed with a lower respiratory tract infection or
pneumonia. Approximately 2.0% of patients received
outpatient oseltamivir treatment requiring hospita-
lization, whereas 2.7% of hospitalized patients in-
curred respiratory failure or death. Among patients
with influenza complications, 18.5% were aged < 6
years, 69.4% were aged 6–65 years, and 12.2% were
aged > 65 years. Thirty-two percent (n=305) had un-
derlying diseases. Most common underlying diseases
reported were chronic lung disease (n=73), metabolic
diseases (n=71), and cardiovascular diseases (n=54).
The complication rates in different age groups and re-
gions were also shown in Table 1. Region D and E,
Figure 2 Number of prescriptions across different age groups and rate of prescription per 1000 persons across different age groups.
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among all regions, did not have the highest complica-
tion nor mortality rates.
Discussion
Our study described the prescription pattern of osel-
tamivir in Taiwan during the 2009 influenza A H1N1 pan-
demic. Oseltamivir was widely used in Taiwan, with an
overall prescription rate of 22.33 per 1000 persons. Des-
pite the majority of outpatient use in school-aged children
and adolescents, a substantially higher proportion of hos-
pitalized patients receiving oseltamivir were those aged 0–
6 years and 65 years or older. Our research did not show
higher utilization of anti-influenza drugs associated with
better outcome in population level during influenzaFigure 3 Number of prescriptions from different medical facilities.pandemic. The benefits of anti-influenza therapy may vary
among different age groups and geographical areas.
During the 2009 influenza A H1N1 pandemic, the US
CDC and the WHO suggested prompt empirical neur-
aminidase inhibitor treatment for those with complicated
illnesses regardless of previous health status and those
at high risk for severe disease, such as children younger
than 2 years old, adults aged 65 years and older, preg-
nant women, and those with chronic heart, lung, liver,
kidney disorders, and weakened immune systems [4,9].
It was also recommended that treatment should start as
early as possible even before definitive diagnostic test
results become available [4,9]. In Taiwan, the govern-
ment provided free anti-influenza treatment through
the NHI system for influenza patients with either
Table 2 Patients (%) receiving outpatient and inpatient
oseltamivir treatment in 2009
Outpatient treatment
(%) (N = 487,278)
Inpatient treatment











Local hospitals 10.9 18.8
Regional hospitals 20.5 56.9
Medical centers 10.9 24.2
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defined danger signs [3]. And this free anti-influenza
treatment policy did influence the usage pattern of anti-
influenza drugs in Taiwan. The first peak of virus isola-
tion of H1N1 in 35–36 week did not coincide with the
usage of oseltamivir (data not shown). This may be
explained by the Taiwan CDC providing free antiviral
agents since August 15, 2009. Despite a concern that
oseltamivir overuse could select resistant viruses, studies
that examined countries with high levels of oseltamivir
use did not find a significant percentage of oseltamivir
resistant influenza virus emerging during H1N1 pandemic
[10-12].
Our study showed that there was a substantial differ-
ence in oseltamivir use among age groups. The highest
outpatient prescription proportion was observed for
those aged 7–18 years old (64.3%), which was probablyTable 3 Oseltamivir prescription and mortality rate in country
review
Country Reference Population (millions) Study period Os
Japan Ref 9 128 Aug 2009- Mar 2010 762
Norway Ref 10 4.8 Jan 2009- Dec 2009 579
US Ref 11 307 Apr 2009- Mar 2010 242
Taiwan This article 23.1 Aug 2009-Dec 2009 223
UK Ref 12 60.6 July 2009- Feb 2010 193
Denmark Ref 13 5.5 Jan 2009- Dec 2009 959
Germany Ref 14 82.6 Oct 2009- Dec 2009 405
France Ref 14 65 Oct 2009- Dec 2009 122
Spain Ref 14 46.6 Oct 2009- Dec 2009 40.
Italy Ref 14 60 Oct 2009- Dec 2009 29.due to the high infectious rate in this age group [13-15].
However, according to current treatment guidelines, pa-
tients in this age group, who have uncomplicated illness
and are not in a group known to be at higher risk of de-
veloping severe or complicated illness, may not need to
be treated with neuraminidase inhibitors [2-4]. In con-
trast, individuals aged 65 years or older had a much
lower outpatient prescription rate (0.8%) despite that
they were more vulnerable to severe influenza-related
complications, if they were to acquire an infection. From
the ICD-9 diagnosis in outpatients department visit in
Taiwan in 2009 pandemic, children and adolescents had
about four-fold higher numbers of ILI visit comparison
to those aged 65 years or older [7]. Children and adoles-
cents had a six-fold higher incidence of seropositivity in
comparison to those aged 65 years or older [13]. How-
ever, children and adolescents (aged 7–18) had a more
than fifty-fold higher numbers of the anti-influenza pre-
scriptions in comparison to those aged 65 years or older
in this study. Similar findings were observed in the US;
clinicians were less likely to provide anti-influenza
agents to adults ≥65 years old with influenza, compared
with younger adults [15]. The low oseltamivir utilization
in elderly may be explained by atypical presentation in
this age group and/or decreased sensitivity of rapid
influenza diagnostic testing [16-18]. The use of rapid
diagnostic tests would ensure oseltamivir were only pre-
scribed to people with confirmed influenza, reducing
inappropriate use [18]. However, reliance on typical in-
fluenza symptoms and rapid influenza diagnostic tests
for clinical decision-making may lead to many influenza
infections going untreated or causing a treatment delay
[16]. A global pooled analysis showed the relative risk of
death was highest in the age groups 50–64 and ≥65
years and the presence of chronic illness increased the
likelihood of death [17]. In Taiwan, the elderly had a
three-fold higher incidence of serious infection comparedlevel during 2009 H1N1 pandemic from literature











Figure 4 Oseltamivir prescription rates and mortality of influenza patients among different countries. X axis: prescription (Log per
100,000 population); Y axis :mortality (per 100,000 population).
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whether there is an over- or under-utilization of anti-
influenza agents among different age groups.
From a literature search from Pubmed, Medline and
Google using keyword “oseltamivir”, “prescription” and
country names, we identified 10 published articles and
governmental reports on oseltamivir prescriptions in
2009 H1N1 pandemic (Table 3) (Figure 4) [19-24]. We
collected the reported number of cumulative confirmed
fatal 2009 pandemic influenza A (H1N1) from European
Centre for Disease Prevention and Control [25]. A sub-
stantial difference in oseltamivir prescription rates was
found among countries, with the highest rates in Japan
and Norway. There was no significant relation between
prescription rate and influenza-associated mortality at
the population level by linear regression (slope of the re-
gression line 0.03; p=0.933). This may be explained by
different prescription policy and accessibility of anti-
influenza drugs during H1N1 pandemic in different
countries. Healthcare accessibility and the lack of a
co-payment for anti-influenza therapy made Taiwan be-
come one of the countries with the highest oseltamivir
utilization in the world. We did not know whether high
mortality even under high oseltamivir prescription was
related to (1) most prescriptions were probably issued
to those people with mild cases of influenza (2) delayed
oseltamivir use; (3) poor prognosis in certain risk groups;
(4) bacterial co-infections [26] or (5) different mortality
definition. Some physical and social factors may impede
access to early use of anti-influenza drugs with the poten-
tial for more serious influenza outcomes. Besides, our data
also showed regional differences in the oseltamivir
utilization and influenza complication rate. In fact, the
oseltamivir utilization rate was higher in northern Taiwanthan southern Taiwan, and the complication rate was
highest in eastern Taiwan. There are many factors that can
influence the regional variations in terms of oseltamivir
utilization rates and influenza complication rates. For ex-
ample, influenza virus activity and number of infected
cases, demographics and clinical risk profiles of the popu-
lation, time to access to the healthcare system, physician
attitude on anti-influenza prescription, and the quality of
outpatient and inpatient care, may all play a role. From
these data, it is difficult to make any conclusion about the
potential relation between oseltamivir use and influenza
outcomes. However, the observed excess variability may
suggest a disparity in terms of resource allocation among
different regions in Taiwan. Public health efforts to over-
come social factors to provide early anti-influenza drugs
access may decrease influenza-related mortality [9]. Fur-
ther study investigating optimal public anti-influenza
drugs delivery and use, and research identifying area of in-
efficiency to correct potential under- or over-utilization is
urgently needed to create strategies to prepare for the
coming influenza pandemics.
There were several limitations in our study. First, the
database did not include self-administered oseltamivir
use. As there was a supply shortage of oseltamivir during
the 2009 H1N1 pandemic, oseltamivir prescription data
in the NHI database could represent the use of anti-
influenza drugs throughout the entire country. Second,
because the accuracy of influenza infection based on
ICD-9-CM diagnostic codes was low, we only examined
the infection outcomes among those who received
oseltamivir treatment. Third, due to a lack of related in-
formation, we only examined the relation between crude
oseltamivir utilization rate and crude influenza-related
mortality without taking into account age distribution.
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In conclusion, our study found that oseltamivir was widely
used during the 2009 H1N1 pandemic in Taiwan, particu-
larly those aged 7–18 years. Further study is needed to
examine whether there is an over- or under-use of anti-
influenza drugs in different age groups or regions and to
examine the current policy of public use of anti-influenza
drugs reduce influenza-associated morbidity and mortality.
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